Compare DexCom, Inc. (DXCM) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs ProShares Ultra QQQ ETF — how do they compare? DexCom, Inc. trades at $78.1 (market cap $28.06B), while ProShares Ultra QQQ ETF trades at $89.75. Which is the better fit depends on your goals.
| DXCM | QLD | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $89.53 | $100.53 |
52-Week Low | $54.84 | $57.16 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
QLD, the ProShares Ultra QQQ ETF, is a 2x daily leveraged fund tracking the Nasdaq-100. The stock trades at $90.15, down 2.14% on the day, with a technical signal leaning bearish. Key financial ratios are not applicable for this ETF structure, which amplifies daily index returns. Recent news highlights its long-term performance and role in tactical portfolios, while technical analysis shows immediate support near $90.
The outlook hinges on the direction of the tech-heavy Nasdaq-100. The fund offers amplified exposure for tactical bullish bets but carries significant volatility and decay risks in sideways or declining markets. Its bearish technical signals and leveraged nature make it suitable only for investors with high risk tolerance and a short-term horizon.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
